ULURU 10-Q15 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	15-May-14	15-May-14
	Mar. 31, 2014	Common Stock [Member]	Series A Preferred Stock [Member]
Entity Information [Line Items]	'	'	'
Entity Registrant Name	'ULURU INC.	'	'
Entity Central Index Key	'0001168220	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	24,338,110	0
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q1	'	'
Document Type	'10-Q	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Mar-14	'	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets	'	'
Cash and cash equivalents	$1,015,778	$5,119
Accounts receivable, net	256,563	185,078
Notes receivable and accrued interest, current portion	0	777,710
Inventory	380,967	395,605
Prepaid expenses and deferred charges	127,843	123,812
Total Current Assets	1,781,151	1,487,324
Property, Equipment and Leasehold Improvements, net	594,055	638,614
Other Assets	'	'
Intangible assets, net	3,553,676	3,670,837
Investment in unconsolidated subsidiary	0	0
Deferred financing costs, net	0	86,770
Deposits	18,069	18,069
Total Other Assets	3,571,745	3,775,676
TOTAL ASSETS	5,946,951	5,901,614
Current Liabilities	'	'
Accounts payable	1,423,807	1,734,725
Accrued liabilities	248,817	315,963
Accrued interest	19,895	13,360
Convertible notes payable, net of unamortized debt discount, current portion	261,793	1,147,057
Deferred revenue, current portion	58,959	58,959
Total Current Liabilities	2,013,271	3,270,064
Long Term Liabilities	'	'
Deferred revenue, net of current portion	883,594	898,133
Total Long Term Liabilities	883,594	898,133
TOTAL LIABILITIES	2,896,865	4,168,197
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' EQUITY	'	'
Preferred stock - $0.001 par value; 20,000 shares authorized; Preferred Stock Series A, 1,000 shares designated; no shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	0	0
Common Stock - $0.001 par value; 200,000,000 shares authorized; 23,588,110 and 18,871,420 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	23,588	18,872
Additional paid-in capital	55,339,540	53,336,127
Accumulated (deficit)	-52,313,042	-51,621,582
TOTAL STOCKHOLDERS' EQUITY	3,050,086	1,733,417
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$5,946,951	$5,901,614

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
STOCKHOLDERS' EQUITY	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	20,000	20,000
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized (in shares)	200,000,000	200,000,000
Common Stock, shares issued (in shares)	23,588,110	18,871,420
Common Stock, shares outstanding (in shares)	23,588,110	18,871,420
Series A Preferred Stock [Member]	'	'
STOCKHOLDERS' EQUITY	'	'
Shares designated to Series A (in shares)	1,000	1,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues	'	'
License fees	$14,539	$11,153
Product sales, net	87,441	90,891
Total Revenues	101,980	102,044
Costs and Expenses	'	'
Cost of goods sold	41,042	40,889
Research and development	187,595	165,285
Selling, general and administrative	469,073	260,690
Amortization of intangible assets	117,161	117,161
Depreciation	60,554	65,388
Total Costs and Expenses	875,425	649,413
Operating (Loss)	-773,445	-547,369
Other Income (Expense)	'	'
Interest and miscellaneous income	4,541	22,465
Interest expense	-65,259	-131,686
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Gain on early extinguishment of convertible note	142,703	0
(Loss) Before Income Taxes	-691,460	-656,590
Income taxes	0	0
Net (Loss)	-691,460	-656,590
Less preferred stock dividends	0	-12,021
Net (Loss) Allocable to Common Stockholders	($691,460)	($668,611)
Basic and diluted net (loss) per common share (in dollars per share)	($0.03)	($0.06)
Weighted average number of common shares outstanding (in shares)	21,416,265	11,657,123

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
OPERATING ACTIVITIES :	'	'
Net loss	($691,460)	($656,590)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of intangible assets	117,161	117,161
Depreciation	60,554	65,388
Share-based compensation for stock and options issued to employees	4,612	1,554
Share-based compensation for options issued to non-employees	19,928	8,418
Equity in earnings (loss) of unconsolidated subsidiary	0	0
Amortization of debt discount on convertible note	19,665	44,778
Amortization of deferred financing costs	7,309	18,844
Warrants issued (cancelled) for services	72,771	-48,776
Common stock issued for services	42,600	0
Common stock issued for interest due on convertible note	2,063	37,918
Gain on early extinguishment of convertible note	-142,703	0
Change in operating assets and liabilities:	'	'
Accounts receivable	-71,485	27,357
Inventory	14,638	21,438
Prepaid expenses and deferred charges	-4,031	58,476
Notes receivable and accrued interest	777,710	240,444
Accounts payable	-310,918	-436,920
Accrued liabilities	-67,146	7,271
Accrued interest	6,535	7,310
Deferred revenue	-14,539	-11,153
Total	534,724	159,508
Net Cash Used in Operating Activities	-156,736	-497,082
INVESTING ACTIVITIES :	'	'
Purchase of property and equipment	-15,996	0
Net Cash Used in Investing Activities	-15,996	0
FINANCING ACTIVITIES :	'	'
Proceeds from sale of common stock and warrants, net	610,000	481,446
Proceeds from exercise of common stock warrants	1,350,000	0
Repayment of principle due on convertible note	-776,609	0
Net Cash Provided by Financing Activities	1,183,391	481,446
Net Increase (Decrease) in Cash	1,010,659	-15,636
Cash, beginning of period	5,119	21,549
Cash, end of period	1,015,778	5,913
SUPPLEMENTAL CASH FLOW DISCLOSURE:	'	'
Cash paid for interest	983	1,264
Non-cash investing and financing activities:	'	'
Issuance of common stock for principle due on convertible note	$317,029	$212,081

COMPANY_OVERVIEW_AND_BASIS_OF_

COMPANY OVERVIEW AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2014
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]	'
COMPANY OVERVIEW AND BASIS OF PRESENTATION	'
	NOTE 1.	COMPANY OVERVIEW AND BASIS OF PRESENTATION

	Company Overview

	ULURU Inc. (hereinafter “we”, “our”, “us”, “ULURU”, or the “Company”) is a Nevada corporation. We are a diversified specialty pharmaceutical company committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products based on our patented Nanoflex® and OraDisc^TM technologies, with the goal of improving outcomes for patients, health care professionals, and health care payers.

	Basis of Presentation

	In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of March 31, 2014 and the results of its operations for the three months ended March 31, 2014 and 2013 and cash flows for the three months ended March 31, 2014 and 2013 have been made.

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates and assumptions. These differences are usually minor and are included in our consolidated financial statements as soon as they are known. Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.

	All intercompany transactions and balances have been eliminated in consolidation.

	Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

	These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, including the risk factors set forth therein.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2.	SIGNIFICANT ACCOUNTING POLICIES

	The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2014 are consistent with those discussed in Note 2 to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014.

THE_EFFECT_OF_RECENTLY_ISSUED_

THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	3 Months Ended
	Mar. 31, 2014
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]	'
THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS	'
	NOTE 3.	THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS

	There were no new accounting pronouncements adopted or enacted during the periods presented that had, or are expected to have, a material impact on our financial statements.

SEGMENT_INFORMATION

SEGMENT INFORMATION	3 Months Ended
SEGMENT INFORMATION	Mar. 31, 2014
SEGMENT INFORMATION [Abstract]	'
SEGMENT INFORMATION	'
	NOTE 4.	SEGMENT INFORMATION

	We operate in one business segment: the research, development and commercialization of pharmaceutical products. Our corporate headquarters in the United States collects product sales, licensing fees, royalties, and sponsored research revenues from our arrangements with external customers and licensees. Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

	Our revenues are currently derived primarily from seven licensees for international activities and our domestic sales activities of Altrazeal®.

	Revenues per geographic area for the three months ended March 31 are summarized as follows:

	Revenues		2014				%				2013		%
	Domestic		$	9,672				9	%		$	19,787		19	%
	International			92,308				91	%			82,257		81	%
	Total		$	101,980				100	%		$	102,044		100	%

	A significant portion of our revenues are derived from a few major customers. Customers with greater than 10% of total sales for the three months ended March 31 are represented on the following table:

	Customers	Product		2014				2013
	Customer A	Altrazeal®			76	%			---
	Customer B	Altrazeal®			*				75	%
	Total				76	%			75	%

	* Sales from this customer were less than 10% of total sales for the period reported.

NOTES_RECEIVABLE

NOTES RECEIVABLE	3 Months Ended
	Mar. 31, 2014
NOTES RECEIVABLE [Abstract]	'
NOTES RECEIVABLE	'
	NOTE 5.	NOTES RECEIVABLE

	On June 27, 2012, we entered into a Securities Purchase Agreement related to our issuance of a $2,210,000 Secured Convertible Note (the “June 2012 Note”), with Inter-Mountain Capital Corp., a Delaware corporation (“Inter-Mountain”). As part of the June 2012 Note transaction, we received $1,500,000 in the form of six promissory notes in favor of the Company, each in the principal amount of $250,000 (the “Investor Notes”) and each of which becomes due as the outstanding balance under the June 2012 Note is reduced to certain levels. As of December 31, 2013, we had $777,710 in notes receivable which is comprised of $687,500 for three Investor Notes and $90,210 for accrued interest thereon.

	On January 22, 2014, we provided notice to Inter-Mountain of our election to exercise our rights under the June 2012 Note and to offset amounts we owed to Inter-Mountain against amounts it owed to us under the Investor Notes. Our notice provided that such deduction and offset occurred on January 22, 2014, that we will not incur the 120% prepayment premium with respect to amounts paid under the June 2012 Note as a result of the deduction and offset, that no warrants will become exercisable as a result of the offset, and that any warrants unvested as of January 22, 2014 shall immediately and automatically terminate. As a result of the deduction and offset, the outstanding amount owed to us under the Investor Notes was reduced to zero.

	Please refer to Note 11. for a more detailed description of the June 2012 Note transaction.

INVENTORY

INVENTORY	3 Months Ended
INVENTORY	Mar. 31, 2014
INVENTORY [Abstract]	'
INVENTORY	'
	NOTE 6.	INVENTORY

	As of March 31, 2014, our inventory was comprised of Altrazeal® finished goods, manufacturing costs incurred in the production of Altrazeal®, and raw materials. Inventories are stated at the lower of cost (first in, first out method) or market. We regularly review inventories on hand and write down the carrying value of our inventories for excess and potentially obsolete inventories based on historical usage and estimated future usage. In assessing the ultimate realization of our inventories, we are required to make judgments as to future demand requirements. As actual future demand or market conditions may vary from those projected by us, adjustment to inventories may be required.

	The components of inventory, at the different stages of production, consisted of the following at March 31, 2014 and December 31, 2013:

	Inventory		31-Mar-14		31-Dec-13
	Finished goods		$	24,261	$	85,993
	Work-in-progress			346,347		299,464
	Raw materials			10,359		10,148
	Total		$	380,967	$	395,605

PROPERTY_EQUIPMENT_and_LEASEHO

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	3 Months Ended
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	Mar. 31, 2014
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]	'
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS	'
	NOTE 7.	PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS

	Property, equipment and leasehold improvements, net, consisted of the following at March 31, 2014 and December 31, 2013:

	Property, equipment and leasehold improvements		31-Mar-14			31-Dec-13
	Laboratory equipment		$	424,888		$	424,888
	Manufacturing equipment			1,597,723			1,581,728
	Computers, office equipment, and furniture			140,360			140,360
	Computer software			4,108			4,108
	Leasehold improvements			95,841			95,841
				2,262,920			2,246,925
	Less: accumulated depreciation and amortization			( 1,668,865	)		(1,608,311	)
	Property, equipment and leasehold improvements, net		$	594,055		$	638,614

	Depreciation expense on property, equipment and leasehold improvements was $60,554 and $65,388 for the three months ended March 31, 2014 and 2013, respectively.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
INTANGIBLE ASSETS	Mar. 31, 2014
INTANGIBLE ASSETS [Abstract]	'
INTANGIBLE ASSETS	'
	NOTE 8.	INTANGIBLE ASSETS

	Intangible assets are comprised of patents acquired in October, 2005. Intangible assets, net consisted of the following at March 31, 2014 and December 31, 2013:

	Intangible assets		31-Mar-14			31-Dec-13
	Patent - Amlexanox (Aphthasol®)		$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)			6,873,080			6,873,080
	Patent - OraDisc™			73,000			73,000
	Patent - Hydrogel nanoparticle aggregate			589,858			589,858
				9,625,938			9,625,938
	Less: accumulated amortization			( 6,072,262	)		(5,955,101	)
	Intangible assets, net		$	3,553,676		$	3,670,837

	Amortization expense for intangible assets was $117,161 and $117,161 for the three months ended March 31, 2014 and 2013, respectively.

	The future aggregate amortization expense for intangible assets, remaining as of March 31, 2014, is as follows:

	Calendar Years		Future
			Amortization
			Expense
	2014 (Nine months)		$	357,987
	2015			475,148
	2016			476,450
	2017			475,148
	2018			475,148
	2019 & Beyond			1,293,795
	Total		$	3,553,676

INVESTMENTS_IN_UNCONSOLIDATED_

INVESTMENTS IN UNCONSOLIDATED ENTITIES	3 Months Ended
	Mar. 31, 2014
INVESTMENTS IN UNCONSOLIDATED ENTITIES [Abstract]	'
INVESTMENTS IN UNCONSOLIDATED ENTITIES	'
	NOTE 9.	INVESTMENTS IN UNCONSOLIDATED ENTITIES

	We use the equity method of accounting for investments in other companies that are not controlled by us and in which our interest is generally between 20% and 50% of the voting shares or we have significant influence over the entity, or both.

	Altrazeal Trading Ltd.

	On January 11, 2012, we executed a shareholders' agreement for the establishment of Altrazeal Trading Ltd., a single purpose entity to be used for the exclusive marketing of Altrazeal® throughout the European Union, Australia, New Zealand, North Africa, and the Middle East. As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal Trading Ltd. On February 1, 2014, Altrazeal Trading Ltd. transferred all of their rights and obligations under the existing shareholders' agreement to Altrazeal Trading GmbH.

	Audited financial statements of Altrazeal Trading Ltd. for the years ended December 31, 2012 and 2013 and unaudited financial statements for the three months ended March 31, 2014 have not been released to us and, therefore, we have not included the effect of the financial activities of Altrazeal Trading Ltd. in our financial statements for each reporting period. We believe that our share of the cumulative losses of Altrazeal Trading Ltd. for the years ended December 31, 2012 and 2013 and for the three months ended March 31, 2014 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting periods and no additional losses would be charged to operations.

	Based upon unaudited financial statements provided by Altrazeal Trading Ltd. for the year ended December 31, 2012, our share of Altrazeal Trading Ltd. losses exceeded the carrying value of our investment, therefore the equity method of accounting was suspended and no additional losses were charged to our operations. Our unrecorded share of Altrazeal Trading Ltd. losses for the year ended December 31, 2012 totaled $82,740.
	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:

	Altrazeal Trading Ltd.		31-Dec-12
	Balance sheet
	Total assets		$	415,248
	Total liabilities		$	205,991
	Total stockholders’ equity		$	209,257
	Statement of operations
	Revenues		$	131,869
	Net (loss)		$	(330,961	)
	ORADISC GmbH

	On October 19, 2012, we executed a shareholders' agreement for the establishment of ORADISC GmbH, a single purpose entity to be used for the exclusive development and marketing of OraDisc™ erodible film technology products. We received a non-dilutable 25% ownership interest in ORADISC GmbH.

	As of March 31, 2014, ORADISC GmbH had not begun operations and accordingly the net book value of the investee assets had not been determined and there were no equity method investee gains or losses for the three months ended March 31, 2014.

	Altrazeal AG

	On February 1, 2014, we executed a shareholders' agreement with Altrazeal AG, a single purpose entity for the marketing of Altrazeal® in several territories, including Africa (markets not already licensed), Latin America, Georgia, Turkmenistan, Ukraine, the Commonwealth of Independent States, Jordan, Syria, Asia and the Pacific (excluding China, Hong Kong, Macau, Taiwan, South Korea, Japan, Australia, and New Zealand). As a result of this transaction, we received a non-dilutable 25% ownership interest in Altrazeal AG.

	Financial statements of Altrazeal AG for the three months ended March 31, 2014 have not been released to us and, therefore, we have not included the effect of the financial activities of Altrazeal AG in our financial statements for such reporting period. We believe that our share of the cumulative losses of Altrazeal AG for the three months ended March 31, 2014 would exceed the carrying value of our investment, therefore the equity method of accounting would be suspended for such reporting period and no additional losses would be charged to operations.

ACCRUED_LIABILITIES

ACCRUED LIABILITIES	3 Months Ended
ACCRUED LIABILITIES	Mar. 31, 2014
ACCRUED LIABILITIES [Abstract]	'
ACCRUED LIABILITIES	'
	NOTE 10.	ACCRUED LIABILITIES

	Accrued liabilities consisted of the following at March 31, 2014 and December 31, 2013:

	Accrued Liabilities		31-Mar-14		31-Dec-13
	Accrued taxes – payroll		$	106,299	$	106,299
	Accrued compensation/benefits			118,194		148,683
	Accrued insurance payable			19,142		60,113
	Accrued property taxes			4,050		---
	Product rebates/returns			17		32
	Other			1,115		836
	Total accrued liabilities		$	248,817	$	315,963

CONVERTIBLE_DEBT

CONVERTIBLE DEBT	3 Months Ended
CONVERTIBLE DEBT	Mar. 31, 2014
CONVERTIBLE DEBT [Abstract]	'
CONVERTIBLE DEBT	'
	NOTE 11.	CONVERTIBLE DEBT

	Convertible Note – June 2012

	On June 27, 2012, we entered into a Securities Purchase Agreement (the “Purchase Agreement”), related to our issuance of the June 2012 Note, with Inter-Mountain. The purchase price for the June 2012 Note was paid $500,000 at closing in cash and $1,500,000 in the form of six Investor Notes in favor of the Company, each in the principal amount of $250,000 at an interest rate of 8.0% per annum, and each of which becomes due as the outstanding balance under the June 2012 Note is reduced to certain levels. The purchase price of the June 2012 Note also reflected a $200,000 original issue discount and $10,000 in attorney’s fees. The Purchase Agreement also includes representations and warranties, restrictive covenants, and indemnification provisions standard for similar transactions.

	The June 2012 Note bears interest at the rate of 8.0% per annum, with monthly installment payments of $83,333 commencing on the date that is the earlier of (i) thirty calendar days after the effective date of a registration statement registering the re-sale of the shares issuable upon conversion under the June 2012 Note or (ii) December 24, 2012, but in no event sooner than September 25, 2012. At our option, subject to certain volume, price, and other conditions, the monthly installment payments on the June 2012 Note may be paid in whole, or in part, in cash or in our Common Stock. If the monthly installment is paid in Common Stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of Common Stock during the preceding twenty trading days. The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of Common Stock during the preceding twenty trading days is less than $0.05.

	At the option of Inter-Mountain, the outstanding principal balance of the June 2012 Note may be converted into shares of our Common Stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. The initial tranche was $710,000 and the six subsequent tranches are each $250,000, plus interest. At our option, the outstanding principal balance of the June 2012 Note, or a portion thereof, may be prepaid in cash at 120% of the amount elected to be prepaid. The June 2012 Note is secured by a Security Agreement pursuant to which we granted to Inter-Mountain a first-priority security interest in the assets held by the Company.

	Events of default under the June 2012 Note include failure to make required payments or to deliver shares upon conversion, the entry of a $100,000 judgment not stayed within 30 days, breach of representations or covenants under the transaction documents, various events associated with insolvency or failure to pay debts, delisting of our Common Stock, a restatement of financial statements, and a default under certain other agreements. In the event of default, the interest rate under the June 2012 Note increases to 18% and the June 2012 Note becomes callable at a premium. In addition, the holder has all remedies under law and equity, including foreclosing on our assets under a Security Agreement with Inter-Mountain.

	As part of the convertible debt financing, Inter-Mountain also received a total of seven warrants (the "Warrants") to purchase, if they all vest, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the Warrants. The Warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively. Each of the three remaining Warrants has terminated, as described below. As of March 31, 2014, we have issued 725,274 shares of Common Stock to Inter-Mountain for the cashless exercise of three warrants that vested prior to February 26, 2013 to purchase 1,571,428 shares of Common Stock. At March 31, 2014, there is one warrant that remains vested but unexercised for 392,857 shares of Common Stock.
	As part of the convertible debt financing, we entered into a Registration Rights Agreement whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein no later than July 27, 2012 and to cause such registration statement to be declared effective no later than ninety days after such filing with the SEC and to keep such registration statement effective for a period of no less than one hundred and eighty days. The Registration Rights Agreement also grants Inter-Mountain piggy-back registration rights with respect to future offerings by the Company. In accordance with our obligations under the Registration Rights Agreement, we filed with the SEC a registration statement that was declared effective on July 31, 2012.

	On October 5, 2012, we and Inter-Mountain entered into a First Amendment to Buyer Trust Deed Note #1 for the purpose of revising certain terms and conditions contained in the Buyer Trust Deed Note #1, to include an updated schedule for the timing of certain payment obligations by Inter-Mountain contained therein.

	On January 22, 2014, we provided notice to Inter-Mountain of our election to exercise our rights under the June 2012 Note and to offset amounts we owed to Inter-Mountain against amounts it owed to us under the Investor Notes. Our notice provided that such deduction and offset occurred on January 22, 2014, that we will not incur the 120% prepayment premium with respect to amounts paid under the June 2012 Note as a result of the deduction and offset, that no warrants will become exercisable as a result of the offset, and that any warrants unvested as of January 22, 2014 shall immediately and automatically terminate. As a result of the deduction and offset, the outstanding amount owed under the June 2012 Note was reduced to approximately $317,000 as of January 22, 2014.

	On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of Common Stock for the final payment of approximately $152,000 due under the June 2012 Note.

	Convertible Note – July 2011

	On July 28, 2011, we completed a convertible debt financing for $125,000 with Mr. Kerry P. Gray, the Company’s Chairman, President, and Chief Executive Officer (the “July 2011 Note”). The July 2011 Note bears interest at the rate of 10.0% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on July 28, 2014. The outstanding principal balance of the July 2011 Note may be converted into shares of the Company’s Common Stock, at the option of the note holder and at any time, at a conversion price of $1.08 per share or 115,741 shares of Common Stock. We may force conversion of the July 2011 Note if our Common Stock trades for a defined period of time at a price greater than $2.16. The July 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements. As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 34,722 shares of the Company’s Common Stock. The warrant has an exercise price of $1.08 per share and is exercisable at any time until July 28, 2016.

	On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $11,542 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the July 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012. Commencing on July 1, 2012, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $11,542 until the relevant payment date. On September 5, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2012 of $11,542 and accrued interest thereon of $1,643.

	On July 1, 2013, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2013 of $12,501 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the July 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2013. Commencing on July 1, 2013, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $12,501 until the relevant payment date. On October 28, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2013 of $12,501 and accrued interest thereon of $492.

	Convertible Note – June 2011

	On June 13, 2011, we completed a $140,000 convertible debt financing with Mr. Gray (the “June 2011 Note”). The June 2011 Note bears interest at the rate of 10% per annum, with annual payments of interest commencing on July 1, 2012. The full amount of principal and any unpaid interest will be due on June 13, 2014. The outstanding principal balance of the June 2011 Note may be converted into shares of the Company’s Common Stock, at the option of the note holder and at any time, at a conversion price of $1.20 per share or 116,667 shares of Common Stock. We may force conversion of the convertible note if our Common Stock trades for a defined period of time at a price greater than $1.80. The June 2011 Note is collateralized by the grant of a security interest in the inventory, accounts receivables, and capital equipment held by the Company. The securities issuable on conversion have not been registered under the Securities Act of 1933 and may not be sold absent registration or an applicable exemption from the registration requirements. As part of the convertible debt financing, Mr. Gray also received a warrant to purchase up to 35,000 shares of the Company’s Common Stock. The warrant has an exercise price of $1.20 per share and is exercisable at any time until June 13, 2016.

	On July 3, 2012, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2012 of $14,653 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the June 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2012. Commencing on July 1, 2012, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $14,653 until the relevant payment date. On September 5, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2012 of $14,653 and accrued interest thereon of $2,080.

	On July 1, 2013, the Company and Mr. Gray entered into a Modification Agreement for the purpose of deferring the annual payment of interest due on July 1, 2013 of $14,001 until such time as Mr. Gray provides written notice to us with such notice being no less than 15 days prior to the relevant payment date. Moreover, the parties agreed that no Event of Default under the June 2011 Note occurred as a result of any failure by us to make the annual payment of interest due on July 1, 2013. Commencing on July 1, 2013, interest at the rate of 12.0% per annum accrued on the deferred interest payment of $14,001 until the relevant payment date. On October 28, 2013, we remitted to Mr. Gray the annual interest due on July 1, 2013 of $14,001 and accrued interest thereon of $553.

	We account for convertible debt using specific guidelines in accordance with U.S. GAAP. We allocated the value of the proceeds received to the convertible instrument and to the warrant on a relative fair value basis. We calculated the fair value of the warrant issued with the convertible instrument using the Black-Scholes valuation method, using the same assumptions used for valuing employee stock options, except the contractual life of the warrant was used. Using the effective interest method, the allocated fair value was recorded as a debt discount and is being amortized over the expected term of the convertible debt to interest expense.

	On the date of issuance of the June 2011 Note, the July 2011 Note, and the June 2012 Note, no portion of the proceeds were attributable to a beneficial conversion feature since the conversion price of the June 2011 Note, the July 2011 Note, and the June 2012 Note exceeded the market price of the Company’s Common Stock.

	Information relating to our convertible notes payable is as follows:

													As of March 31, 2014
	Transaction		Initial		Interest			Maturity		Conversion			Principal			Unamortized			Carrying
			Principal		Rate			Date		Price (1)			Balance			Debt			Value
			Amount													Discount
	June 2011 Note		$	140,000		10	%	6/13/14		$	1.2		$	140,000		$	810		$	139,190
	July 2011 Note			125,000		10	%	7/28/14		$	1.08			125,000			2,397			122,603
	Total		$	265,000									$	265,000		$	3,207		$	261,793

	-1	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.

	The amount of interest cost recognized from our convertible notes payable was $13,945 and $45,228 for the three months ended March 31, 2014 and 2013, respectively. The amount of debt discount amortized from our convertible notes payable was $19,665 and $44,778 for the three months ended March 31, 2014 and 2013, respectively.

	The future minimum payments relating to our convertible notes payable, as of March 31, 2014, are as follows:

			Payments Due By Period
	Transaction		Total		2014 (Nine Months)				2015			2016			2017			2018
	June 2011 Note		$	140,000	$	140,000			$	---		$	---		$	---		$	---
	July 2011 Note			125,000		125,000				---			---			---			---
	Total		$	265,000	$	265,000			$	---		$	---		$	---		$	---

EQUITY_TRANSACTIONS

EQUITY TRANSACTIONS	3 Months Ended
	Mar. 31, 2014
EQUITY TRANSACTIONS [Abstract]	'
EQUITY TRANSACTIONS	'
	NOTE 12.	EQUITY TRANSACTIONS

	Common Stock Transactions

	March 2013 Offering

	On March 14, 2013, we entered into a Securities Purchase Agreement (the “March SPA”) with Kerry P. Gray, the Company’s Chairman, President, and Chief Executive Officer and Terrance K. Wallberg, the Company’s Vice President and Chief Financial Officer (collectively, the “Investors”) relating to an equity investment of $440,000 by the Investors for 1,100,000 shares of our Common Stock (the “March Shares”) and warrants to purchase up to 660,000 shares of our Common Stock (the “March Warrants”) (the “March 2013 Offering”). Under the March SPA, the purchase and sale of the March Shares and March Warrants took place at four closings over twelve months, with $88,000 being funded at the initial closing under the March SPA, $110,000 being funded on the four-month anniversary of the initial closing, $132,000 being funded on the eight-month anniversary of the initial closing, and $110,000 being funded on the one-year anniversary of the initial closing. The March Warrants have a fixed exercise price of $0.60 per share, become exercisable in tranches on each of the four funding dates, and expire on the five-year anniversary of the initial closing. On March 14, 2013, we closed the March 2013 Offering and received the initial funding tranche of $88,000 for the purchase of 220,000 shares of our Common Stock. We received subsequent funding tranches of $110,000, $132,000, and $110,000 for the purchase of 275,000, 330,000, and 275,000 shares of our Common Stock on July 15, 2013, November 14, 2013, and March 14, 2014, respectively.

	January 2013 Offering

	On December 21, 2012, we entered into a Securities Purchase Agreement (the “SPA”) with IPMD GmbH (“IPMD”) relating to an equity investment of $2,000,000 by IPMD for 5,000,000 shares of our Common Stock (the “Shares”) and warrants to purchase up to 3,000,000 shares of our Common Stock (the “Warrants”) (the “January 2013 Offering”). Under the SPA, the purchase and sale of the Shares and Warrants took place at four closings over twelve months, with $400,000 being funded at the initial closing under the SPA, $500,000 being funded on the four-month anniversary of the initial closing, $600,000 being funded on the eight-month anniversary of the initial closing, and $500,000 being funded on the one-year anniversary of the initial closing. The Warrants have a fixed exercise price of $0.60 per share, become exercisable in tranches on each of the four funding dates, and expire on the one-year anniversary of the initial closing. On January 3, 2013, we closed the January 2013 Offering and received the initial funding tranche of $400,000 for the purchase of 1,000,000 shares of our Common Stock. We received subsequent funding tranches of $500,000, $300,000, $300,000, and $500,000 for the purchase of 1,250,000, 750,000, 750,000, and 1,250,000 shares of our Common Stock on May 7, 2013, September 6, 2013, October 24, 2013, and January 6, 2014 respectively.

	In the SPA, we also agree to appoint up to two directors nominated by IPMD to serve on our Board of Directors. On January 17, 2013, the Board of Directors of the Company appointed Helmut Kerschbaumer and Klaus Kuehne to each serve as a director of the Company. Messrs. Kerschbaumer and Kuehne are the designees of IPMD to serve on the Company’s Board of Directors pursuant to covenants in the SPA with IPMD.

	On January 3, 2014, the Warrants vested with respect to 3,000,000 shares of our Common Stock and were exercised by IPMD on that date pursuant to a Notice of Exercise, accepted by the Company, that provided for the issuance of 750,000 shares of Common Stock on each of January 31, 2014, February 28, 2014, March 31, 2014, and April 30, 2014 in exchange for the payment of $450,000 on each such date.

	On January 31, 2014, IPMD entered into an Assignment Agreement (the “Assignment Agreement”) with The Punch Trust (“TPT”) and Michael I. Sacks (“Sacks”) pursuant to which IPMD assigned to TPT and Sacks its rights and interests to purchase up to 3,000,000 shares of our Common Stock as detailed in the Warrants and the Notice of Exercise. Neither TPT nor Sacks paid any monetary consideration to IPMD in connection with the assignments under the Assignment Agreement.

	Concurrent with the assignment under the Assignment Agreement described above, ULURU, TPT, Sacks, and IPMD entered into an Implementation Agreement (the “Implementation Agreement”) pursuant to which we consented and agreed to the assignment of the Warrants to TPT and Sacks. We also agreed to issue and facilitate the delivery of the shares of Common Stock under the Warrants to TPT and Sacks upon their payment of the corresponding purchase price due under the Warrants. Under the terms of the Warrants, Sacks made payments of $450,000 on each of January 31, 2014 and February 28, 2014 and $150,000 on each of March 31, 2014 and April 30, 2014. The Company issued 750,000 shares of Common Stock to Sacks on each of January 31, 2014 and February 28, 2014 and 250,000 shares of Common Stock on each of March 31, 2014 and April 30, 2014. Under the terms of the Warrants, TPT made payments of $300,000 on each of March 31, 2014 and April 30, 2014 and the Company issued 500,000 shares of Common Stock to TPT on each date, respectively.

	On January 31, 2014, we also entered into a Registration Rights Agreement with TPT and Sacks whereby we agreed to prepare and file with the SEC a registration statement for the number of shares referred to therein within sixty days after request and to use commercially reasonable efforts to cause such registration statement to be declared effective with the SEC and to keep such registration statement effective for a period of eighty days and, if necessary, such eighty day period being extended for up to sixty additional days.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
STOCKHOLDERS' EQUITY	Mar. 31, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
STOCKHOLDERS' EQUITY	'
	NOTE 13.	STOCKHOLDERS’ EQUITY

	Common Stock

	As of March 31, 2014, we had 23,588,110 shares of Common Stock issued and outstanding. We issued 4,716,690 shares of Common Stock for the three months ended March 31, 2014 comprised of 1,250,000 shares of Common Stock issued to IPMD pursuant to the January 2013 Offering, 275,000 shares of Common Stock issued to Messrs. Gray and Wallberg pursuant to the March 2013 Offering, 911,690 shares of Common Stock issued for installment payments and note conversion on the June 2012 Note with Inter-Mountain, 2,250,000 shares of Common Stock issued for the exercise of warrants held by Sacks and TPT, and 30,000 shares of Common Stock issued for consulting services.

	Preferred Stock

	As of March 31, 2014, we had no shares of Series A Preferred Stock (the “Series A Shares”). For the three months ended March 31, 2014, we did not issue or redeem any Series A Shares.

	Warrants

	The following table summarizes the warrants outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2014 and the changes therein during the three months then ended:

			Number of Shares of			Weighted – Average
			Common Stock Subject			Exercise Price
			to Exercise
	Balance as of December 31, 2013			4,665,451		$	0.82
	Warrants issued			80,000		$	1.2
	Warrants exercised			(2,250,000	)	$	0.6
	Warrants cancelled			---			---
	Balance as of March 31, 2014 (1)			2,495,451		$	1.03

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated. For the purposes of this Table, only such net vested shares of Common Stock from one unexercised warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of Common Stock.

	For the three months ended March 31, 2014, we issued a warrant to Torrey Hills Capital, Inc., to purchase up to an aggregate of 80,000 shares of our Common Stock at an exercise price of $1.20 per share, for consulting services.

	Of the warrant shares subject to exercise as of March 31, 2014, expiration of the right to exercise is as follows:

	Date of Expiration		Number of
			Warrant Shares
			of Common
			Stock Subject to
			Expiration
	30-Apr-14			750,000
	23-Jul-14			69,050
	15-May-15			357,155
	13-Jun-16			35,000
	16-Jul-16			116,667
	28-Jul-16			34,722
	27-Jun-17			392,857
	14-Mar-18			660,000
	15-Jan-19			80,000
	Total			2,495,451

EARNINGS_PER_SHARE

EARNINGS PER SHARE	3 Months Ended
EARNINGS PER SHARE	Mar. 31, 2014
EARNINGS PER SHARE [Abstract]	'
EARNINGS PER SHARE	'
	NOTE 14.	EARNINGS PER SHARE

	Basic and Diluted Net Loss Per Share

	In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 260, Earnings per Share, basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period, increased to include potential dilutive common shares. The effect of outstanding stock options, restricted vesting Common Stock, convertible debt, convertible preferred stock, and warrants, when dilutive, is reflected in diluted earnings (loss) per common share by application of the treasury stock method. We have excluded all outstanding stock options, restricted vesting Common Stock, convertible debt, convertible preferred stock, and warrants from the calculation of diluted net loss per common share because all such securities are antidilutive for all periods presented.

	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of March 31, 2014 and December 31, 2013:

			31-Mar-14		31-Dec-13
	Warrants to purchase Common Stock			2,495,451		4,665,451
	Stock options to purchase common stock			1,014,907		1,014,907
	Unvested restricted common stock			---		---
	Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 (1)			---		3,124,680
	Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 (2)			241,386		253,315
	Total			3,751,744		9,058,353

	-1	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of Common Stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations. On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of Common Stock for the final payment of approximately $152,000 due under the June 2012 Note.
	-2	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of Common Stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be March 31, 2014.

SHARE_BASED_COMPENSATION

SHARE BASED COMPENSATION	3 Months Ended
SHARE BASED COMPENSATION	Mar. 31, 2014
SHARE BASED COMPENSATION [Abstract]	'
SHARE BASED COMPENSATION	'
	NOTE 15.	SHARE BASED COMPENSATION

	The Company’s share-based compensation plan, the 2006 Equity Incentive Plan, as amended (“Equity Incentive Plan”), is administered by the compensation committee of the Board of Directors (“Board”), which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provisions of the award.

	Our Board granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the three months ended March 31:

			Three Months Ended March 31,
			2014 (1)				2013
	Incentive Stock Options
	Quantity			---				232,500
	Weighted average fair value per share			---			$	0.24
	Fair value			---			$	56,112

	Nonstatutory Stock Options
	Quantity			---				735,000
	Weighted average fair value per share			---			$	0.24
	Fair value			---			$	177,388

	-1	The Company did not award any shared-based compensation for the three months ended March 31, 2014.

	We account for share-based compensation under FASB ASC Topic 718, Stock Compensation, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values of the award on the grant date. We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards with the following weighted average assumptions for the three months ended March 31:

			Three Months Ended March 31,
			2014 (4)				2013
	Incentive Stock Options
	Expected volatility (1)			---				103.55	%
	Risk-free interest rate % (2)			---				0.81	%
	Expected term (in years)			---				5
	Dividend yield (3)			---				---
	Forfeiture rate			---				---

	Nonstatutory Stock Options
	Expected volatility (1)			---				103.55	%
	Risk-free interest rate % (2)			---				0.81	%
	Expected term (in years)			---				5
	Dividend yield (3)			---				---
	Forfeiture rate			---				---

	-1	Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility
	-2	Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.
	-3	The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.
	-4	The Company did not award any shared-based compensation for the three months ended March 31, 2014.

	Stock Options (Incentive and Nonstatutory)

	The following table summarizes share-based compensation related to stock options for the three months ended March 31:

			Three Months Ended
			March 31,
			2014				2013
	Research and development		$	5,307			$	648
	Selling, general and administrative			19,233				8,333
	Total share-based compensation expense		$	24,540			$	8,981

	At March 31, 2014, the balance of unearned share-based compensation to be expensed in future periods related to unvested stock option awards, as adjusted for expected forfeitures, is approximately $127,903. The period over which the unearned share-based compensation is expected to be recognized is approximately two years.

	The following table summarizes the stock options outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2014 and the changes therein during the three months then ended:

			Stock Options				Weighted
							Average
							Exercise
							Priceper
							Share
Outstanding as of December 31, 2013			1,014,907			$	2.12
Granted			---				---
Forfeited/cancelled			---				---
Exercised			---				---
Outstanding as of March 31, 2014			1,014,907			$	2.12

The following table presents the stock option grants outstanding and exercisable as of March 31, 2014:

Options Outstanding										Options Exercisable
Stock Options				Weighted				Weighted		Stock		Weighted
Outstanding				Average				Average		Options		Average
				Exercise Price				Remaining		Exercisable		Exercise Price
				per Share				Contractual Life				per Share
								in Years
	892,500			$	0.33				9		272,500	$	0.33
	53,334				2.38				4.2		46,668		2.36
	30,002				14.4				3		30,002		14.4
	39,071				33.35				3.6		39,071		33.35
	1,014,907			$	2.12				8.3		388,241	$	4.98

Restricted Stock Awards

Restricted stock awards, which typically vest over a period of two to five years, are issued to certain key employees and are subject to forfeiture until the end of an established restriction period. We utilize the market price on the date of grant as the fair market value of restricted stock awards and expense the fair value on a straight-line basis over the vesting period.

The following table summarizes share-based compensation related to restricted stock awards for the three months ended March 31:

		Three Months Ended
		March 31,
		2014				2013
Research and development			---			$	444
Selling, general and administrative			---				547
Total share-based compensation expense			---			$	991

At March 31, 2014, the balance of unearned share-based compensation to be expensed in future periods related to restricted stock awards, as adjusted for expected forfeitures, is zero.

The following table summarizes the non-vested restricted stock awards outstanding and the number of shares of Common Stock subject to potential issue as of March 31, 2014 and the changes therein during the three months then ended:

		Restricted				Weighted Average
		stock				Grant Date Fair
						Value
Outstanding as of December 31, 2013			---				---
Shares granted			---				---
Shares forfeited/cancelled			---				---
Shares exercised/issued			---				---
Outstanding as of March 31, 2014			---				---

Summary of Plans

2006 Equity Incentive Plan

In March 2006, our Board adopted and our stockholders approved our Equity Incentive Plan, which initially provided for the issuance of up to 133,333 shares of our Common Stock pursuant to stock option and other equity awards. At the annual meetings of the stockholders held on May 8, 2007, December 17, 2009, June 15, 2010, June 14, 2012, and on June 13, 2013, our stockholders approved amendments to the Equity Incentive Plan to increase the total number of shares of Common Stock issuable under the Equity Incentive Plan pursuant to stock options and other equity awards by 266,667 shares, 200,000 shares, 200,000 shares, 400,000 shares, and 600,000 shares, respectively, to a total of 1,800,000 shares.

In December 2006, we began issuing stock options to employees, consultants, and directors. The stock options issued generally vest over a period of one to four years and have a maximum contractual term of ten years. In January 2007, we began issuing restricted stock awards to our employees. Restricted stock awards generally vest over a period of six months to five years after the date of grant. Prior to vesting, restricted stock awards do not have dividend equivalent rights, do not have voting rights and the shares underlying the restricted stock awards are not considered issued and outstanding. Shares of Common Stock are issued on the date the restricted stock awards vest.

As of March 31, 2014, we had granted options to purchase 1,376,167 shares of Common Stock since the inception of the Equity Incentive Plan, of which 1,014,907 were outstanding at a weighted average exercise price of $2.12 per share, and we had granted awards for 68,616 shares of restricted stock since the inception of the Equity Incentive Plan, of which none were outstanding. As of March 31, 2014, there were 715,647 shares that remained available for future grants under our Equity Incentive Plan.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
FAIR VALUE MEASUREMENTS	Mar. 31, 2014
FAIR VALUE MEASUREMENTS [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	NOTE 16.	FAIR VALUE MEASUREMENTS

	In accordance with FASB ASC Topic 820, Fair Value Measurements, (“ASC Topic 820”) certain assets and liabilities of the Company are required to be recorded at fair value. Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants. The guidance in ASC Topic 820 also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimized the use of unobservable inputs by requiring that the most observable inputs be used when available.

	Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on our market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

	The three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies, is as follows:

		Level 1	—Valuations based on quoted prices (unadjusted) for identical assets or liabilities in active markets.

		Level 2	—Valuations based on observable inputs other than quoted prices in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable or can be corroborated by observable market data.

		Level 3	—Valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants.

	Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurements. We review the fair value hierarchy classification on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.

	Our financial instruments, including cash, cash equivalents, accounts receivable, and accounts payable are carried at cost, which approximates their fair value because of the short-term maturity of these instruments. We believe that the carrying value of our other receivable and convertible note payable balances approximates fair value based on a valuation methodology using the income approach and a discounted cash flow model.

	The following table summarizes the fair value of our financial instruments at March 31, 2014 and December 31, 2013.

	Description		31-Mar-14		31-Dec-13
	Assets:
	Notes receivable and accrued interest			---	$	777,710

	Liabilities:
	Convertible note – June 2011		$	139,190	$	138,220
	Convertible note – July 2011		$	122,603	$	120,738
	Convertible note – June 2012			---	$	888,099

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2014
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 17.	INCOME TAXES

	There was no current federal tax provision or benefit recorded for any period since inception, nor were there any recorded deferred income tax assets, as such amounts were completely offset by valuation allowances.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 18.	COMMITMENTS AND CONTINGENCIES

	Operating Leases

	On January 31, 2006 we entered into a lease agreement for office and laboratory space in Addison, Texas. The lease commenced on April 1, 2006 and originally continued until April 1, 2013. The lease required a minimum monthly lease obligation of $9,330, which was inclusive of monthly operating expenses, until April 1, 2011 and at such time increased to $9,776, which was inclusive of monthly operating expenses. On February 22, 2013, we executed an Amendment to Lease Agreement (the “Lease Amendment”) that renewed and extended our lease until March 31, 2015. The Lease Amendment requires a minimum monthly lease obligation of $9,193, which is inclusive of monthly operating expenses, until March 31, 2014 and at such time, will increase to $9,379, which is inclusive of monthly operating expenses.

	On December 10, 2010 we entered into a lease agreement for certain office equipment. The lease, which commenced on February 1, 2011 and continues until February 1, 2015, requires a minimum lease obligation of $744 per month.

	The future minimum lease payments under the 2013 office lease and the 2010 equipment lease are as follows as of March 31, 2014:

	Calendar Years		Future Lease Expense
	2014 (Nine months)		$	91,106
	2015			28,881
	2016			---
	2017			---
	2018			---
	Total		$	119,987

	Rent expense for our operating leases amounted to $30,380 and $25,028 for the three months ended March 31, 2014 and 2013, respectively.

	Indemnification

	In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future, but have not yet been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record charges in the future as a result of these indemnification obligations.

	In accordance with our restated articles of incorporation and our amended and restated bylaws, we have indemnification obligations to our officers and directors for certain events or occurrences, subject to certain limits, while they are serving at our request in their respective capacities. There have been no claims to date and we have a director and officer insurance policy that enables us to recover a portion of any amounts paid for future potential claims. We have also entered into contractual indemnification agreements with each of our officers and directors.

	Related Party Transactions and Concentration

	On January 17, 2013, the Board of Directors of the Company appointed Helmut Kerschbaumer and Klaus Kuehne to each serve as a director of the Company. Mr. Kerschbaumer currently serves as a director of IPMD, Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG (collectively, the “Altrazeal Distributors”) and Mr. Kuehne currently serves as a director of Altrazeal AG. In such capacities, Mr. Kerschbaumer may be considered, either singularly or collectively, to have control of, and make investment and business decisions on behalf of the Altrazeal Distributors and Mr. Kuehne may be considered, either singularly of collectively, to have control of, and make investment and business decisions on behalf of Altrazeal AG.

	Currently, we are party to License and Supply Agreements with Altrazeal Trading GmbH, Altrazeal AG, and Melmed Holding AG for the marketing and distribution of Altrazeal in various international territories. On December 21, 2012, we entered into a Securities Purchase Agreement with IPMD as described in more detail in Note 12.

	For the three months ended March 31, 2014 and 2013, the Company recorded product sales, in approximate numbers, of $78,000 and $71,000, respectively, with the various Altrazeal Distributors, which represented 76% and 70% of our total revenues. As of March 31, 2014 and December 31, 2013, Altrazeal Distributors had an outstanding accounts receivable, in approximate numbers, of $252,000 and $174,000, respectively, which represented 97% and 97% of our total outstanding accounts receivables.

	Related Party Obligations

	Since 2011, our named executive officers and certain key executives have temporarily deferred portions of their compensation as part of a plan to conserve the Company’s cash and financial resources.

	As of March 31, 2014, the following table summarizes the compensation temporarily deferred and subsequent repayments:

	Name		2014			2013			2012		2011		Total
	Kerry P. Gray (1) (2)		$	(97,500	)	$	(91,000	)	$	220,673	$	140,313	$	172,486
	Terrance K. Wallberg			---			(35,769	)	$	24,230	$	36,539	$	25,000
	Key executives			(17,188	)		(20,000	)	$	27,253	$	20,986	$	11,051
	Total		$	(114,688	)	$	(146,769	)	$	272,156	$	197,838	$	208,537

	-1	During 2014, Mr. Gray temporarily deferred compensation of $15,000 earned for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2014, Mr. Gray was also repaid $112,500 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
	-2	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

	As of March 31, 2014 and December 31, 2013, the Company’s obligation for temporarily deferred compensation was $208,537, of which $122,500 was included in accounts payable and $86,037 was included in accrued liabilities, and $323,225 of which $207,500 was included in accounts payable and $115,725 was included in accrued liabilities, respectively.

	Contingent Milestone Obligations

	We are subject to paying Access Pharmaceuticals, Inc. (“Access”) for certain milestones based on our achievement of certain annual net sales, cumulative net sales, and/or our having reached certain defined technology milestones including licensing agreements and advancing products to clinical development. As of March 31, 2014, the future milestone obligations that we are subject to paying Access, if the milestones related thereto are achieved, total $4,750,000. Such milestones are based on total annual sales of 20 and 40 million dollars of certain products, annual sales of 20 million dollars of any one certain product, and cumulative sales of such products of 50 and 100 million dollars.

	On March 7, 2008, we terminated the license agreement with ProStrakan Ltd. for Amlexanox-related products in the United Kingdom and Ireland. As part of the termination, we agreed to pay ProStrakan Ltd. a royalty of 30% on any future payments received by us from a new licensee in the United Kingdom and Ireland territories, up to a maximum of $1,400,000. On November 17, 2008, we entered into a licensing agreement for Amlexanox-related product rights to the United Kingdom and Ireland territories with MEDA AB.

LEGAL_PROCEEDINGS

LEGAL PROCEEDINGS	3 Months Ended
	Mar. 31, 2014
LEGAL PROCEEDINGS [Abstract]	'
LEGAL PROCEEDINGS	'
	NOTE 19.	LEGAL PROCEEDINGS

	From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. We are not currently a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on the results of our operations or financial position. There are no material proceedings to which any director, officer or any of our affiliates, any owner of record or beneficially of more than five percent of any class of our voting securities, or any associate of any such director, officer, our affiliates, or security holder, is a party adverse to us or our consolidated subsidiary or has a material interest adverse thereto.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 20.	SUBSEQUENT EVENTS

	Under the terms of the warrants held by Sacks and TPT, on April 30, 2014 we received payments of $150,000 and $300,000 from Sacks and TPT, respectively, and we issued 250,000 and 500,000 shares of Common Stock to Sacks and TPT, respectively.

COMPANY_OVERVIEW_AND_BASIS_OF_1

COMPANY OVERVIEW AND BASIS OF PRESENTATION (Policies)	3 Months Ended
COMPANY OVERVIEW AND BASIS OF PRESENTATION (Policies)	Mar. 31, 2014
COMPANY OVERVIEW AND BASIS OF PRESENTATION [Abstract]	'
Basis of Presentation	'
	Basis of Presentation

	In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and include the accounts of ULURU Inc., a Nevada corporation, and its wholly-owned subsidiary, Uluru Delaware Inc., a Delaware corporation. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position as of March 31, 2014 and the results of its operations for the three months ended March 31, 2014 and 2013 and cash flows for the three months ended March 31, 2014 and 2013 have been made.

	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates and assumptions. These differences are usually minor and are included in our consolidated financial statements as soon as they are known. Our estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from those estimates.

	All intercompany transactions and balances have been eliminated in consolidation.

	Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

	These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on March 31, 2014, including the risk factors set forth therein.

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	3 Months Ended
SEGMENT INFORMATION (Tables)	Mar. 31, 2014
SEGMENT INFORMATION [Abstract]	'
Revenues per geographic area	'
	Revenues per geographic area for the three months ended March 31 are summarized as follows:

	Revenues		2014				%				2013		%
	Domestic		$	9,672				9	%		$	19,787		19	%
	International			92,308				91	%			82,257		81	%
	Total		$	101,980				100	%		$	102,044		100	%
Customers with greater than 10% of total sales	'
	A significant portion of our revenues are derived from a few major customers. Customers with greater than 10% of total sales for the three months ended March 31 are represented on the following table:

	Customers	Product		2014				2013
	Customer A	Altrazeal®			76	%			---
	Customer B	Altrazeal®			*				75	%
	Total				76	%			75	%

	* Sales from this customer were less than 10% of total sales for the period reported.

INVENTORY_Tables

INVENTORY (Tables)	3 Months Ended
INVENTORY (Tables)	Mar. 31, 2014
INVENTORY [Abstract]	'
Components of inventory	'
	The components of inventory, at the different stages of production, consisted of the following at March 31, 2014 and December 31, 2013:

	Inventory	31-Mar-14		31-Dec-13
	Finished goods	$	24,261	$	85,993
	Work-in-progress		346,347		299,464
	Raw materials		10,359		10,148
	Total	$	380,967	$	395,605

PROPERTY_EQUIPMENT_and_LEASEHO1

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Tables)	3 Months Ended
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Tables)	Mar. 31, 2014
PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS [Abstract]	'
Property, equipment and leasehold improvements	'
	Property, equipment and leasehold improvements, net, consisted of the following at March 31, 2014 and December 31, 2013:

	Property, equipment and leasehold improvements	31-Mar-14			31-Dec-13
	Laboratory equipment	$	424,888		$	424,888
	Manufacturing equipment		1,597,723			1,581,728
	Computers, office equipment, and furniture		140,360			140,360
	Computer software		4,108			4,108
	Leasehold improvements		95,841			95,841
			2,262,920			2,246,925
	Less: accumulated depreciation and amortization		( 1,668,865	)		(1,608,311	)
	Property, equipment and leasehold improvements, net	$	594,055		$	638,614

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
INTANGIBLE ASSETS (Tables)	Mar. 31, 2014
INTANGIBLE ASSETS [Abstract]	'
Intangible assets	'
	Intangible assets are comprised of patents acquired in October, 2005. Intangible assets, net consisted of the following at March 31, 2014 and December 31, 2013:

	Intangible assets	31-Mar-14			31-Dec-13
	Patent - Amlexanox (Aphthasol®)	$	2,090,000		$	2,090,000
	Patent - Amlexanox (OraDisc™ A)		6,873,080			6,873,080
	Patent - OraDisc™		73,000			73,000
	Patent - Hydrogel nanoparticle aggregate		589,858			589,858
			9,625,938			9,625,938
	Less: accumulated amortization		( 6,072,262	)		(5,955,101	)
	Intangible assets, net	$	3,553,676		$	3,670,837
Future aggregate amortization expense for intangible assets	'
	The future aggregate amortization expense for intangible assets, remaining as of March 31, 2014, is as follows:

	Calendar Years	Future
		Amortization
		Expense
	2014 (Nine months)	$	357,987
	2015		475,148
	2016		476,450
	2017		475,148
	2018		475,148
	2019 & Beyond		1,293,795
	Total	$	3,553,676

INVESTMENTS_IN_UNCONSOLIDATED_1

INVESTMENTS IN UNCONSOLIDATED ENTITIES (Tables)	3 Months Ended
INVESTMENTS IN UNCONSOLIDATED ENTITIES (Tables)	Mar. 31, 2014
INVESTMENTS IN UNCONSOLIDATED ENTITIES [Abstract]	'
Summarized financial information for investment	'
	Summarized financial information for our investment in Altrazeal Trading Ltd. assuming 100% ownership is as follows:

	Altrazeal Trading Ltd.	31-Dec-12
	Balance sheet
	Total assets	$	415,248
	Total liabilities	$	205,991
	Total stockholders’ equity	$	209,257
	Statement of operations
	Revenues	$	131,869
	Net (loss)	$	(330,961	)

ACCRUED_LIABILITIES_Tables

ACCRUED LIABILITIES (Tables)	3 Months Ended
ACCRUED LIABILITIES (Tables)	Mar. 31, 2014
ACCRUED LIABILITIES [Abstract]	'
Accrued liabilities	'
	Accrued liabilities consisted of the following at March 31, 2014 and December 31, 2013:

	Accrued Liabilities	31-Mar-14		31-Dec-13
	Accrued taxes – payroll	$	106,299	$	106,299
	Accrued compensation/benefits		118,194		148,683
	Accrued insurance payable		19,142		60,113
	Accrued property taxes		4,050		---
	Product rebates/returns		17		32
	Other		1,115		836
	Total accrued liabilities	$	248,817	$	315,963

CONVERTIBLE_DEBT_Tables

CONVERTIBLE DEBT (Tables)	3 Months Ended
CONVERTIBLE DEBT (Tables)	Mar. 31, 2014
CONVERTIBLE DEBT [Abstract]	'
Information relating to convertible notes payable	'
	Information relating to our convertible notes payable is as follows:

													As of March 31, 2014
	Transaction		Initial		Interest			Maturity		Conversion			Principal			Unamortized			Carrying
			Principal		Rate			Date		Price (1)			Balance			Debt			Value
			Amount													Discount
	June 2011 Note		$	140,000		10	%	6/13/14		$	1.2		$	140,000		$	810		$	139,190
	July 2011 Note			125,000		10	%	7/28/14		$	1.08			125,000			2,397			122,603
	Total		$	265,000									$	265,000		$	3,207		$	261,793

	-1	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.
Schedule of future minimum payments relating to our convertible notes payable	'
	The future minimum payments relating to our convertible notes payable, as of March 31, 2014, are as follows:

			Payments Due By Period
	Transaction		Total		2014 (Nine Months)				2015			2016			2017			2018
	June 2011 Note		$	140,000	$	140,000			$	---		$	---		$	---		$	---
	July 2011 Note			125,000		125,000				---			---			---			---
	Total		$	265,000	$	265,000			$	---		$	---		$	---		$	---

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
STOCKHOLDERS' EQUITY (Tables)	Mar. 31, 2014
STOCKHOLDERS' EQUITY [Abstract]	'
Warrants outstanding and number of shares of common stock subject to exercise	'
	The following table summarizes the warrants outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2014 and the changes therein during the three months then ended:

			Number of Shares of			Weighted – Average
			Common Stock Subject			Exercise Price
			to Exercise
	Balance as of December 31, 2013			4,665,451		$	0.82
	Warrants issued			80,000		$	1.2
	Warrants exercised			(2,250,000	)	$	0.6
	Warrants cancelled			---			---
	Balance as of March 31, 2014 (1)			2,495,451		$	1.03

	-1	As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated. For the purposes of this Table, only such net vested shares of Common Stock from one unexercised warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of Common Stock.
Expiration dates for warrants subject to exercise	'
	Of the warrant shares subject to exercise as of March 31, 2014, expiration of the right to exercise is as follows:

	Date of Expiration		Number of
			Warrant Shares
			of Common
			Stock Subject to
			Expiration
	30-Apr-14			750,000
	23-Jul-14			69,050
	15-May-15			357,155
	13-Jun-16			35,000
	16-Jul-16			116,667
	28-Jul-16			34,722
	27-Jun-17			392,857
	14-Mar-18			660,000
	15-Jan-19			80,000
	Total			2,495,451

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	3 Months Ended
EARNINGS PER SHARE (Tables)	Mar. 31, 2014
EARNINGS PER SHARE [Abstract]	'
Common shares excluded from calculating basic and diluted net loss per common share	'
	Shares used in calculating basic and diluted net loss per common share exclude these potential common shares as of March 31, 2014 and December 31, 2013:

			31-Mar-14		31-Dec-13
	Warrants to purchase Common Stock			2,495,451		4,665,451
	Stock options to purchase common stock			1,014,907		1,014,907
	Unvested restricted common stock			---		---
	Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 (1)			---		3,124,680
	Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 (2)			241,386		253,315
	Total			3,751,744		9,058,353

	-1	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of Common Stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations. On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of Common Stock for the final payment of approximately $152,000 due under the June 2012 Note.
	-2	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of Common Stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be March 31, 2014.

SHARE_BASED_COMPENSATION_Table

SHARE BASED COMPENSATION (Tables)	3 Months Ended
SHARE BASED COMPENSATION (Tables)	Mar. 31, 2014
SHARE BASED COMPENSATION [Abstract]	'
Stock option awards granted	'
	Our Board granted the following incentive stock option awards to executives or employees and nonstatutory stock option awards to directors or non-employees for the three months ended March 31:

			Three Months Ended March 31,
			2014 (1)				2013
	Incentive Stock Options
	Quantity			---				232,500
	Weighted average fair value per share			---			$	0.24
	Fair value			---			$	56,112

	Nonstatutory Stock Options
	Quantity			---				735,000
	Weighted average fair value per share			---			$	0.24
	Fair value			---			$	177,388

	-1	The Company did not award any shared-based compensation for the three months ended March 31, 2014.
Weighted average assumptions to estimate the fair value of share based awards	'
	We use the Black-Scholes option-pricing model to estimate the fair value of share-based awards with the following weighted average assumptions for the three months ended March 31:

			Three Months Ended March 31,
			2014 (4)				2013
	Incentive Stock Options
	Expected volatility (1)			---				103.55	%
	Risk-free interest rate % (2)			---				0.81	%
	Expected term (in years)			---				5
	Dividend yield (3)			---				---
	Forfeiture rate			---				---

	Nonstatutory Stock Options
	Expected volatility (1)			---				103.55	%
	Risk-free interest rate % (2)			---				0.81	%
	Expected term (in years)			---				5
	Dividend yield (3)			---				---
	Forfeiture rate			---				---

	-1	Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility
	-2	Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.
	-3	The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.
	-4	The Company did not award any shared-based compensation for the three months ended March 31, 2014.
Allocated share-based compensation expense	'
	The following table summarizes share-based compensation related to stock options for the three months ended March 31:

			Three Months Ended
			March 31,
			2014				2013
	Research and development		$	5,307			$	648
	Selling, general and administrative			19,233				8,333
	Total share-based compensation expense		$	24,540			$	8,981
Stock option activity	'
	The following table summarizes the stock options outstanding and the number of shares of Common Stock subject to exercise as of March 31, 2014 and the changes therein during the three months then ended:

			Stock Options				Weighted
							Average
							Exercise
							Priceper
							Share
	Outstanding as of December 31, 2013			1,014,907			$	2.12
	Granted			---				---
	Forfeited/cancelled			---				---
	Exercised			---				---
	Outstanding as of March 31, 2014			1,014,907			$	2.12
Stock option grants outstanding and exercisable	'
	The following table presents the stock option grants outstanding and exercisable as of March 31, 2014:

	Options Outstanding										Options Exercisable
	Stock Options				Weighted				Weighted		Stock		Weighted
	Outstanding				Average				Average		Options		Average
					Exercise Price				Remaining		Exercisable		Exercise Price
					per Share				Contractual Life				per Share
									in Years
		892,500			$	0.33				9		272,500	$	0.33
		53,334				2.38				4.2		46,668		2.36
		30,002				14.4				3		30,002		14.4
		39,071				33.35				3.6		39,071		33.35
		1,014,907			$	2.12				8.3		388,241	$	4.98
Nonvested restricted stock awards	'
	The following table summarizes share-based compensation related to restricted stock awards for the three months ended March 31:

			Three Months Ended
			March 31,
			2014				2013
	Research and development			---			$	444
	Selling, general and administrative			---				547
	Total share-based compensation expense			---			$	991

	At March 31, 2014, the balance of unearned share-based compensation to be expensed in future periods related to restricted stock awards, as adjusted for expected forfeitures, is zero.

	The following table summarizes the non-vested restricted stock awards outstanding and the number of shares of Common Stock subject to potential issue as of March 31, 2014 and the changes therein during the three months then ended:

			Restricted				Weighted Average
			stock				Grant Date Fair
							Value
	Outstanding as of December 31, 2013			---				---
	Shares granted			---				---
	Shares forfeited/cancelled			---				---
	Shares exercised/issued			---				---
	Outstanding as of March 31, 2014			---				---

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Mar. 31, 2014
FAIR VALUE MEASUREMENTS [Abstract]	'
Fair value of financial instruments	'
	The following table summarizes the fair value of our financial instruments at March 31, 2014 and December 31, 2013.

	Description	31-Mar-14		31-Dec-13
	Assets:
	Notes receivable and accrued interest		---	$	777,710

	Liabilities:
	Convertible note – June 2011	$	139,190	$	138,220
	Convertible note – July 2011	$	122,603	$	120,738
	Convertible note – June 2012		---	$	888,099

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Mar. 31, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
Future minimum lease payments	'
	The future minimum lease payments under the 2013 office lease and the 2010 equipment lease are as follows as of March 31, 2014:

	Calendar Years		Future Lease Expense
	2014 (Nine months)		$	91,106
	2015			28,881
	2016			---
	2017			---
	2018			---
	Total		$	119,987
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred	'
	As of March 31, 2014, the following table summarizes the compensation temporarily deferred and subsequent repayments:

	Name		2014			2013			2012		2011		Total
	Kerry P. Gray (1) (2)		$	(97,500	)	$	(91,000	)	$	220,673	$	140,313	$	172,486
	Terrance K. Wallberg			---			(35,769	)	$	24,230	$	36,539	$	25,000
	Key executives			(17,188	)		(20,000	)	$	27,253	$	20,986	$	11,051
	Total		$	(114,688	)	$	(146,769	)	$	272,156	$	197,838	$	208,537

	-1	During 2014, Mr. Gray temporarily deferred compensation of $15,000 earned for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2014, Mr. Gray was also repaid $112,500 of temporarily deferred compensation, of which $100,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.
	-2	During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
	Licensee
	Segment
SEGMENT INFORMATION [Abstract]	'		'
Number of business segments	1		'
Number of international licensees	7		'
Revenues per geographic area [Abstract]	'		'
Total Revenues	$101,980		$102,044
Total revenue, percentage (in hundredths)	100.00%		100.00%
Revenue, Major Customer [Line Items]	'		'
Sales from major customer, percentage (in hundredths)	76.00%		75.00%
Customer A [Member] \| Altrazeal [Member]	'		'
Revenue, Major Customer [Line Items]	'		'
Sales from major customer, percentage (in hundredths)	76.00%		0.00%
Customer B [Member] \| Aphthasol [Member]	'		'
Revenue, Major Customer [Line Items]	'		'
Sales from major customer, percentage (in hundredths)	'	[1]	75.00%
Domestic [Member]	'		'
Revenues per geographic area [Abstract]	'		'
Total Revenues	9,672		19,787
Total revenue, percentage (in hundredths)	9.00%		19.00%
International [Member]	'		'
Revenues per geographic area [Abstract]	'		'
Total Revenues	$92,308		$82,257
Total revenue, percentage (in hundredths)	91.00%		81.00%

[1]	Sales from this customer were less than 10% of total sales for the period reported.

NOTES_RECEIVABLE_Details

NOTES RECEIVABLE (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2012
	PromissoryNote	PromissoryNote
Information relating to convertible notes payable [Abstract]	'	'
Initial principal amount	$265,000	'
June 2012 Note [Member]	'	'
Information relating to convertible notes payable [Abstract]	'	'
Initial principal amount	2,210,000	'
Percentage of prepayment premium of debt (in hundredths)	120.00%	'
Secured convertible note [Member] \| June 2012 Note [Member]	'	'
Information relating to convertible notes payable [Abstract]	'	'
Purchase price paid in the form of promissory notes	1,500,000	1,500,000
Number of promissory notes issued under purchase agreement	6	6
Principal amount of promissory notes	250,000	250,000
Notes receivable and accrued interest	777,710	'
Notes receivable	687,500	'
Accrued interest	$90,210	'

INVENTORY_Details

INVENTORY (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Components of inventory [Abstract]	'	'
Finished goods	$24,261	$85,993
Work-in-progress	346,347	299,464
Raw materials	10,359	10,148
Total	$380,967	$395,605

PROPERTY_EQUIPMENT_and_LEASEHO2

PROPERTY, EQUIPMENT and LEASEHOLD IMPROVEMENTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	$2,262,920	'	$2,246,925
Less: accumulated depreciation and amortization	-1,668,865	'	-1,608,311
Property, equipment and leasehold improvements, net	594,055	'	638,614
Depreciation expense	60,554	65,388	'
Laboratory Equipment [Member]	'	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	424,888	'	424,888
Manufacturing Equipment [Member]	'	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	1,597,723	'	1,581,728
Computers, Office Equipment, and Furniture [Member]	'	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	140,360	'	140,360
Computer Software [Member]	'	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	4,108	'	4,108
Leasehold Improvements [Member]	'	'	'
Property, equipment and leasehold improvements, net [Abstract]	'	'	'
Property, equipment and leasehold improvements, gross	$95,841	'	$95,841

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended
INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intangible assets, gross	$9,625,938	'	$9,625,938
Less: accumulated amortization	-6,072,262	'	-5,955,101
Intangible assets, net	3,553,676	'	3,670,837
Amortization expense	117,161	117,161	'
Future aggregate amortization expense for intangible assets [Abstract]	'	'	'
2014 (Nine months)	357,987	'	'
2015	475,148	'	'
2016	476,450	'	'
2017	475,148	'	'
2018	475,148	'	'
2019 & Beyond	1,293,795	'	'
Total	3,553,676	'	'
Patents [Member] \| Amlexanox (Aphthasol) [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intangible assets, gross	2,090,000	'	2,090,000
Patents [Member] \| Amlexanox (OraDiscA) [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intangible assets, gross	6,873,080	'	6,873,080
Patents [Member] \| OraDisc [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intangible assets, gross	73,000	'	73,000
Patents [Member] \| Hydrogel Nanoparticle Aggregate [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Intangible assets, gross	$589,858	'	$589,858

INVESTMENTS_IN_UNCONSOLIDATED_2

INVESTMENTS IN UNCONSOLIDATED ENTITIES (Details) (USD $)	3 Months Ended				12 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
	Mar. 31, 2014	Mar. 31, 2013	Minimum [Member]	Maximum [Member]	Altrazeal Trading Ltd. [Member]	Altrazeal Trading Ltd. [Member]	OraDisc [Member]	OraDisc [Member]
Schedule of Equity Method Investments [Line Items]	'	'	'	'	'	'	'	'
Percentage of noncontrolling interest (in hundredths)	'	'	20.00%	50.00%	'	'	'	'
Non-dilutable ownership interest (in hundredths)	'	'	'	'	25.00%	25.00%	'	25.00%
Unrecorded profit (loss)	'	'	'	'	$82,740	'	'	'
Balance sheet [Abstract]	'	'	'	'	'	'	'	'
Total assets	'	'	'	'	415,248	'	'	'
Total liabilities	'	'	'	'	205,991	'	'	'
Total stockholders' equity	'	'	'	'	209,257	'	'	'
Statement of operations [Abstract]	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	131,869	'	'	'
Net (loss)	'	'	'	'	-330,961	'	'	'
Gains losses on equity method investments	$0	$0	'	'	'	'	$0	'

ACCRUED_LIABILITIES_Details

ACCRUED LIABILITIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued liabilities [Abstract]	'	'
Accrued taxes - payroll	$106,299	$106,299
Accrued compensation/benefits	118,194	148,683
Accrued insurance payable	19,142	60,113
Accrued property taxes	4,050	0
Product rebates/returns	17	32
Other	1,115	836
Total accrued liabilities	$248,817	$315,963

CONVERTIBLE_DEBT_Details

CONVERTIBLE DEBT (Details) (USD $)

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Jul. 31, 2011

Jun. 30, 2011

Jun. 13, 2011

Jul. 31, 2011

Mar. 31, 2014

Jun. 27, 2012

Jul. 15, 2013

Feb. 26, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Mar. 31, 2014

Jun. 30, 2011

Mar. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Mar. 31, 2014

Jan. 22, 2014

Mar. 31, 2014

Dec. 31, 2012

Warrant - June 2011 Debt Offering [Member]

Warrant - July 2011 Debt Offering [Member]

Warrant - June 2012 Debt Offering [Member]

Common Stock [Member]

Inter-Mountain [Member]

June 2011 Note [Member]

July 2011 Note [Member]

June 2012 Note [Member]

Secured convertible note [Member]

Warrant

June 2011 Note [Member]

July 2011 Note [Member]

June 2012 Note [Member]

Maximum [Member]

PromissoryNote

Tranche

Debt Instrument [Line Items]

Purchase price paid in cash

$500,000

Purchase price paid in the form of promissory notes

1,500,000

Number of promissory notes issued under purchase agreement

Principal amount of promissory notes

250,000

Original issue discount reflected in purchase price

200,000

Attorney's fees reflected in purchase price

10,000

Amount of monthly installment

83,333

Number of calendar days after the date of registration to commence monthly installment

'30 days

Monthly installment payment terms

'If the monthly installment is paid in common stock, such shares being issued will be based on a price that is 80% of the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days. The percentage declines to 70% if the average of the three lowest volume weighted average prices of the shares of common stock during the preceding twenty trading days is less than $0.05.

Percentage of weighted average prices of shares of common stock (in hundredths)

80.00%

Declined percentage of weighted average prices of shares of common stock (in hundredths)

70.00%

Preceding number of trading days to calculate weighted average common stock price

'20 days

Weighted average price of shares of common stock, Maximum (in dollars per share)

$0.05

Amount convertible under initial tranche

710,000

Number of subsequent tranches

Amount of each subsequent tranche plus interest

250,000

Percentage of outstanding principal balance prepaid in cash (in hundredths)

120.00%

Entry amount of judgment not stayed

100,000

Period within which judgment not stayed

'30 days

Increased interest rate in the event of default (in hundredths)

18.00%

Conversion number of equity instruments (in shares)

116,667

115,741

Stock price trigger (in dollars per share)

$2.16

Annual principal payment

14,001

14,653

12,501

11,542

Notice prior to the relevant payment date

'15 days

Amortization of debt discount on convertible notes

19,665

44,778

Information relating to convertible notes payable [Abstract]

Initial principal amount

265,000

2,210,000

140,000

125,000

Interest Rate (in hundredths)

12.00%

10.00%

12.00%

10.00%

8.00%

Maturity Date

13-Jun-14

28-Jul-14

Conversion Price (in dollars per share)

$0.35

$1.08

$1.20

[1]

$1.80

$1.08

[1]

Principal Balance

265,000

140,000

125,000

Unamortized Debt Discount

3,207

810

2,397

Carrying Value

261,793

139,190

122,603

Interest cost recognized

13,945

45,228

Interest Payable

553

2,080

492

1,643

Deferred interest payable

14,001

14,653

12,501

11,542

Percentage of prepayment premium not incurred as per notice (in hundredths)

120.00%

Reduction of notes payable

317,000

Shares issued (in shares)

435,502

Current maturity of long-term debt

152,000

Future Minimum payments due, convertible notes [Abstract]

2014 (Nine Months)

265,000

140,000

125,000

2015

2016

2017

2018

Total

$265,000

$140,000

$125,000

Class of Warrant or Right [Line Items]

Number of warrants

Number of securities called by warrants (in shares)

35,000

34,722

3,142,857

1,571,428

3,142,857

Exercise price of warrants (in dollars per share)

$0.35

$1.20

$1.08

$0.35

Number of warrants that vest upon payment of notes (in shares)

Number of securities vested (in shares)

785,714

392,857

Shares issued on exercise of warrants

2,250,000

725,274

Warrants exercised (in shares)

2,250,000

1,571,428

Number of warrants that vest upon payment of notes but unexercised (in shares)

Unexercised shares issued for warrants (in shares)

1,392,587

Minimum period during which registration statement is to be declared effective after filing with SEC

'90 days

Maximum period during which registration statement is to be declared effective after filing with SEC

'180 days

[1]

The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per shares, respectively.

EQUITY_TRANSACTIONS_Details

EQUITY TRANSACTIONS (Details) (USD $)

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

Jan. 31, 2014

Mar. 31, 2014

Mar. 14, 2014

Feb. 28, 2014

Jan. 31, 2014

Jan. 06, 2014

Nov. 14, 2013

Oct. 24, 2013

Sep. 06, 2013

Jul. 15, 2013

7-May-13

Mar. 14, 2013

Jan. 03, 2013

Jan. 03, 2014

Apr. 30, 2014

Mar. 31, 2014

Mar. 14, 2013

Mar. 31, 2014

Dec. 21, 2012

Mar. 31, 2014

Feb. 28, 2014

Jan. 31, 2014

Apr. 30, 2014

Mar. 31, 2014

Apr. 30, 2014

SPA [Member]

Common Stock [Member]

Director

Subsequent Event [Member]

March SPA [Member]

SPA [Member]

Sacks [Member]

TPT [Member]

Four-month anniversary [Member]

Eight-month anniversary [Member]

One-year anniversary [Member]

Four-month anniversary [Member]

Eight-month anniversary [Member]

One-year anniversary [Member]

Subsequent Event [Member]

Common Stock Transactions [Abstract]

Equity investment

$440,000

$2,000,000

Share price (in dollars per share)

$0.60

Issuance of shares of common stock under securities purchase agreement (in shares)

1,100,000

5,000,000

Number of securities called by warrants (in shares)

3,000,000

660,000

3,000,000

Maximum amount of common stock purchased under common stock purchase agreement

88,000

110,000

132,000

110,000

400,000

500,000

600,000

500,000

Proceeds from offering

$450,000

$110,000

$450,000

$500,000

$132,000

$300,000

$110,000

$500,000

$88,000

$400,000

$450,000

$150,000

$450,000

$150,000

$300,000

Shares purchased under stock purchased agreement (in shares)

275,000

1,250,000

330,000

750,000

275,000

1,250,000

220,000

1,000,000

Number of maximum directors that could be appointed

Shares issued on exercise of warrants (in shares)

2,250,000

750,000

Issuance of shares of common stock under assignment agreement (in shares)

250,000

750,000

250,000

500,000

Number of days within which request is declared effective

'60 days

Number of days for which statement is effective

'80 days

Number of additional days for which filing of statement can be done

'60 days

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS' EQUITY (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Jul. 15, 2013

Feb. 26, 2013

Dec. 31, 2012

Jun. 27, 2012

Jan. 22, 2014

Mar. 31, 2014

Inter-Mountain [Member]

Torrey Hills Capital, Inc. [Member]

Warrant - June 2012 Debt Offering [Member]

April 30, 2014 [Member]

July 23, 2014 [Member]

May 15, 2015 [Member]

June 13, 2016 [Member]

July 16, 2016 [Member]

July 28, 2016 [Member]

June 27, 2017 [Member]

March 14, 2018 [Member]

January 15, 2019 [Member]

Series A Preferred Stock [Member]

Warrant

Private Placement [Member]

Inter-Mountain [Member]

Warrant

Common Stock [Abstract]

Common Stock, shares issued (in shares)

23,588,110

18,871,420

Common Stock, shares outstanding (in shares)

23,588,110

18,871,420

Common stock issued during period (in shares)

4,716,690

Number of shares of common stock issued for IPMD pursuant (in shares)

1,250,000

Stock issued in lieu of offering agreement (in shares)

275,000

Number shares of common stock issued for installment payments (in shares)

911,960

Shares issued on exercise of warrants (in shares)

2,250,000

725,274

Stock Issued During Period, Shares, Issued for Consulting Services

30,000

Preferred Stock [Abstract]

Preferred stock, shares issued (in shares)

Preferred stock, shares outstanding (in shares)

Warrants and Number of Shares of Common Stock Subject to Exercise [Roll Forward]

Balance (in shares)

4,665,451

392,857

785,714

750,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

80,000

Warrants issued (in shares)

80,000

Warrants exercised (in shares)

-2,250,000

-1,571,428

Warrants cancelled (in shares)

Balance (in shares)

2,495,451

[1]

392,857

785,714

750,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

80,000

Warrants, Weighted-Average Exercise Price [Abstract]

Balance (in dollars per share)

$0.82

Warrants issued (in dollars per share)

$1.20

Warrants exercised (in dollars per share)

$0.60

Warrants cancelled (in dollars per share)

Balance (in dollars per share)

$1.03

[1]

Warrant shares subject to expiration [Abstract]

Number of Warrant Shares of Common Stock Subject to Expiration (in shares)

2,495,451

[1]

392,857

785,714

750,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

80,000

Number of warrants to purchase common stock (in shares)

Aggregate shares of common stock issued upon exercise of warrants (in shares)

1,571,428

3,142,857

80,000

3,142,857

Number of warrants exercised (in shares)

Exercise price of warrants (in dollars per share)

$0.35

$1.20

$0.35

Number of unexercised warrants (in shares)

Common stock vested upon initial warrant (in shares)

2,495,451

[1]

392,857

785,714

750,000

69,050

357,155

35,000

116,667

34,722

392,857

660,000

80,000

Number of warrants terminated (in shares)

[1]

As part of the June 2012 Note, Inter-Mountain received a total of seven warrants to purchase, if they all had vested, an aggregate of 3,142,857 shares of Common Stock, which number of shares could increase based upon the terms and conditions of the warrants. The warrants have an exercise price of $0.35 per share, subject to certain pricing adjustments, and are exercisable, subject to vesting provisions and ownership limitations, until June 27, 2017. Warrants for 785,714, 392,857, 392,857, and 392,857 shares of Common Stock vested on June 27, 2012, December 31, 2012, February 26, 2013, and July 15, 2013, respectively, and three warrants for 1,571,428 shares of Common Stock were exercised in 2013. On January 22, 2014, we elected to offset and deduct the three remaining Investor Notes from the principle amount due to Inter-Mountain under the June 2012 Note and as a result of the offset and deduction the three remaining warrants terminated. For the purposes of this Table, only such net vested shares of Common Stock from one unexercised warrant (392,857 shares) have been included, based upon an exercise price of $0.35 per share of Common Stock.

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		12 Months Ended
EARNINGS PER SHARE (Details) (USD $)	Mar. 31, 2014		Dec. 31, 2013		Jul. 31, 2011	Jun. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	3,751,744		9,058,353		'	'
Average number of trading days prior to the payment of note taken to calculate the conversion price	'5 days		'		'	'
Conversion price (in dollars per share)	$0.35		'		$1.08	$1.20
Common stock issued from convertible note payable	435,502		'		'	'
Value of convertilble notes for which shares were issued	$152,000		'		'	'
Warrants to purchase common stock [Member]	'		'		'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	2,495,451		4,665,451		'	'
Stock options to purchase common stock [Member]	'		'		'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	1,014,907		1,014,907		'	'
Unvested restricted common stock [Member]	'		'		'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	0		0		'	'
Common stock issuable upon the assumed conversion of our convertible note payable from June 2012 [Member]	'		'		'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	0	[1]	3,124,680	[1]	'	'
Common stock issuable upon the assumed conversion of our convertible notes payable from June 2011 and July 2011 [Member]	'		'		'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'		'		'	'
Antidilutive securities excluded from calculating basic and diluted net loss per common share (in shares)	241,386	[2]	253,315	[2]	'	'

[1]	The outstanding principal balance and the accrued and unpaid interest of the June 2012 Note may be converted, at the option of Inter-Mountain, into shares of Common Stock at a conversion price of $0.35 per share, subject to certain pricing adjustments and ownership limitations. For the purposes of this Table, we have assumed a conversion price of $0.35 per share and no ownership limitations. On February 27, 2014 and on March 3, 2014, we received conversion notices from Inter-Mountain whereby we issued an aggregate of 435,502 shares of Common Stock for the final payment of approximately $152,000 due under the June 2012 Note.
[2]	The outstanding principal balance of the June 2011 Note and the July 2011 Note may be converted, at the option of Mr. Gray, into shares of Common Stock at a fixed conversion price of $1.20 per share and $1.08 per share, respectively. The accrued and unpaid interest for each convertible note payable may be converted, at the option of Mr. Gray, into shares of Common Stock at a conversion price based upon the average of the five trading days prior to the payment date, which for the purposes of this Table we have assumed to be March 31, 2014.

SHARE_BASED_COMPENSATION_Detai

SHARE BASED COMPENSATION (Details) (USD $)

0 Months Ended

3 Months Ended

Jun. 13, 2013

Jun. 14, 2012

Jun. 15, 2010

Dec. 17, 2009

8-May-07

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2006

Mar. 31, 2014

Incentive Stock Options [Member]

Nonstatutory Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

2006 Equity Incentive Plan [Member]

Minimum [Member]

Maximum [Member]

Stock Options [Member]

Restricted Stock [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Options Granted [Abstract]

Quantity (in shares)

[1]

232,500

[1]

735,000

Weighted average fair value per share (in dollars per share)

[1]

$0.24

[1]

$0.24

Fair value

[1]

$56,112

[1]

$177,388

Weighted average assumptions to estimate the fair value of share-based awards [Abstract]

Expected volatility (in hundredths)

0.00%

[1],[2]

103.55%

[2]

0.00%

[1],[2]

103.55%

[2]

Risk-fee interest rate % (in hundredths)

0.00%

[1],[3]

0.81%

[3]

0.00%

[1],[3]

0.81%

[3]

Expected term (in years)

'0 years

[1]

'5 years

[1]

'0 years

[1]

'5 years

[1]

Dividend yield (in hundredths)

0.00%

[1],[4]

0.00%

[4]

0.00%

[1],[4]

0.00%

[4]

Forfeiture rate (in hundredths)

0.00%

[1]

0.00%

[1]

0.00%

Options, Outstanding [Roll Forward]

Outstanding, beginning of period (in shares)

1,014,907

Granted (in shares)

[1]

232,500

[1]

735,000

Forfeited/cancelled (in shares)

Exercised (in shares)

Outstanding, end of period (in shares)

1,014,907

Outstanding, Weighted Average Exercise Price [Roll Forward]

Outstanding, beginning of period (in dollars per share)

$2.12

Granted (in dollars per share)

Forfeited/cancelled (in dollars per share)

Exercised (in dollars per share)

Outstanding, end of period (in dollars per share)

$2.12

Nonvested restricted stock awards, Number of Shares [Roll Forward]

Outstanding, beginning of period (in shares)

Granted (in shares)

Forfeited/cancelled (in shares)

Exercised/issued (in shares)

Outstanding, end of period (in shares)

Nonvested restricted stock awards, Weighted Average Grant Date Fair Value [Roll Forward]

Outstanding, beginning of period (in dollars per share)

Granted (in dollars per share)

Forfeited/cancelled (in dollars per share)

Exercised/issued (in dollars per share)

Outstanding, end of period (in dollars per share)

Additional disclosures [Abstract]

Vesting period

'2 years

'5 years

'1 year

'4 years

'6 months

'5 years

Number of shares authorized (in shares)

1,800,000

133,333

Number of additional shares authorized (in shares)

600,000

400,000

200,000

266,667

Contractual term

'10 years

Number of options granted to date (in shares)

1,376,167

Number of restricted shares granted to date (in shares)

68,616

Number of shares available for grant (in shares)

715,647

Nonvested Awards, unearned share-based compensation [Abstract]

Unearned share-based compensation expense

$127,903

Unearned share-based compensation, recognition period

'2 months

[1]

The Company did not award any shared-based compensation for the three months ended March 31, 2014.

[2]

Expected volatility assumption was based upon a combination of historical stock price volatility measured on a daily basis and an estimate of expected future stock price volatility

[3]

Risk-free interest rate assumption is based upon U.S. Treasury bond interest rates appropriate for the term of the stock options.

[4]

The Company does not currently intend to pay cash dividends, thus has assumed a 0% dividend yield.

SHARE_BASED_COMPENSATION_Alloc

SHARE BASED COMPENSATION, Allocated Compensation expense (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	$24,540	$8,981
Stock Options [Member] \| Research and Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	5,307	648
Stock Options [Member] \| Selling, General and Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	19,233	8,333
Restricted Stock [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	0	991
Restricted Stock [Member] \| Research and Development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	0	444
Restricted Stock [Member] \| Selling, General and Administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Share-based compensation expense	$0	$547

SHARE_BASED_COMPENSATION_Stock

SHARE BASED COMPENSATION, Stock options grant outstanding and exercisable (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in shares)	1,014,907
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$2.12
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'8 years 3 months 18 days
Stock Options Exercisable (in shares)	388,241
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$4.98
Exercise Price Range 1 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in shares)	892,500
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'9 years
Stock Options Exercisable (in shares)	272,500
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$0.33
Exercise Price Range 2 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in shares)	53,334
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$2.38
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'4 years 2 months 12 days
Stock Options Exercisable (in shares)	46,668
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$2.36
Exercise Price Range 3 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in shares)	30,002
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$14.40
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'3 years
Stock Options Exercisable (in shares)	30,002
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$14.40
Exercise Price Range 4 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Stock Options Outstanding (in shares)	39,071
Options Outstanding, Weighted Average Exercise Price per Share (in dollars per share)	$33.35
Options Outstanding, Weighted Average Remaining Contractual Life in Years	'3 years 7 months 6 days
Stock Options Exercisable (in shares)	39,071
Options Exercisable, Weighted Average Exercise Price per Share (in dollars per share)	$33.35

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets [Abstract]	'	'
Notes receivable and accrued interest	$0	$777,710
Convertible note - June 2011 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	139,190	138,220
Convertible note - July 2011 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	122,603	120,738
Convertible note - June 2012 [Member]	'	'
Liabilities [Abstract]	'	'
Convertible note payable	$0	$888,099

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

23 Months Ended

84 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

Dec. 31, 2013

Mar. 31, 2014

Mar. 07, 2008

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2012

Mar. 31, 2013

Mar. 31, 2014

Feb. 22, 2013

Mar. 31, 2013

Mar. 31, 2014

Access Pharmaceuticals [Member]

ProStrakan Ltd [Member]

Kerry P. Gray [Member]

Terrance K. Wallberg [Member]

Key Executives [Member]

Altrazeal Trading Ltd. [Member]

Office and Laboratory Space [Member]

Office Equipment [Member]

Annual Sales, Certain Products [Member]

Annual Sales, Any One Certain Product [Member]

Cumulative Sales, Certain Products [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Operating Leased Assets [Line Items]

Minimum monthly lease obligation

$9,193

$9,776

$9,330

$744

Future minimum monthly lease obligation after specified period

9,379

Future minimum lease payments [Abstract]

2013 (Three months)

91,106

2014

28,881

2015

2016

2017

Total

119,987

Rent expense for operating lease

30,380

25,028

Related Party Obligations [Abstract]

Related party sales

78,000

71,000

Outstanding accounts receivable

252,000

174,000

Concentration risk, percentage (in hundredths)

76.00%

75.00%

76.00%

70.00%

97.00%

Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]

Deferred compensation liability

-114,688

-146,769

272,156

197,838

-97,500

[1],[2]

-91,000

[1],[2]

220,673

[1],[2]

140,313

[1],[2]

-35,769

24,230

36,539

-17,188

-20,000

27,253

20,986

Deferred compensation

208,537

323,225

172,486

[1],[2]

221,500

25,000

11,051

Deferred compensation liability pursuant to separation agreement

11,500

Deferred compensation liability pursuant to duties as chairman

15,000

210,000

Repayment of temporarily deferred compensation

112,500

312,500

Proceeds from issuance of common stock under March 2013 offering

100,000

300,000

Compensation accounts payable

122,500

207,500

Compensation accrued liabilities

86,037

115,725

Milestone payments [Line Items]

Future milestone obligations

4,750,000

1,400,000

Milestone for payment

$20,000,000

$40,000,000

$20,000,000

$50,000,000

$100,000,000

Royalty percentage (in hundredths)

30.00%

[1]

During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Companybs Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

[2]

During 2013, Mr. Gray temporarily deferred compensation of $169,000 which consisted of $11,500 earned pursuant to a Separation Agreement and $157,500 for his duties as Chairman of the Executive Committee of the Companybs Board of Directors. During 2013, Mr. Gray was also repaid $192,500 of temporarily deferred compensation, of which $180,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.

LEGAL_PROCEEDINGS_Details

LEGAL PROCEEDINGS (Details)	3 Months Ended
LEGAL PROCEEDINGS (Details)	Mar. 31, 2014
LEGAL PROCEEDINGS [Abstract]	'
Percentage of voting securities (in hundredths)	5.00%

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (Subsequent Event [Member], Common Stock [Member], USD $)	0 Months Ended
	Apr. 30, 2014
Sacks [Member]	'
Subsequent Event [Line Items]	'
Proceeds from offering	$150,000
Issuance of shares of common stock under assignment agreement (in shares)	250,000
TPT [Member]	'
Subsequent Event [Line Items]	'
Proceeds from offering	$300,000
Issuance of shares of common stock under assignment agreement (in shares)	500,000